Yes. Organizations may use the same clinical quality measure for each program if the measure is relevant to each program's population. Each program's population must be measured separately.
Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can ask a question through My NCQA.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Print this page.
Print this page.
Yes. The example on page 114 should read as follows:
100 out of 100 PCPs meet the criteria = 100%
_ 5 points for certified and 3.75 for non-certified
25 of 100 certified = ((25% * 5) = 1.25)
75 of 100 non-certified = ((75% * 3.75) = 2.81)
Total points = ((1.25+ 2.81) = 4.06)
The example on page 115, in the Point allocation for POs using ONC-ATCB certified software section, should read as follows:
For example, if a PO earned 60 points, its overall calculated P4P score would be 18. Scores are rounded to the nearest whole number.
These errors will be corrected in the September 2012 release of the MY 2012 manual.
There is an error in the manual. The first date in the example should be November 30, 2010. The full example should read as follows:
For example, in the MY 2011 Breast Cancer Screening measure (which requires 2 years of continuous enrollment), a member who disenrolls on November 30, 2010 (the year prior to the measurement year), and re-enrolls on February 1, 2011 (the measurement year), is considered continuously enrolled as long as there were no other gaps in enrollment during either year. The member has one gap of 31 days (December 1_31) in 2010 and one gap of 31 days (January 1_31) in 2011.
This error will be corrected in the September 2012 release of the MY 2012 manual.
There is an error in the manual. In Table CWP-C: Antibiotic Medications,
in the row First generation cephalosporins, the drug Cephradine should not be in the table,
in the row Macrolides the drug Erythromycin estolate should not be in the table,
in the row Third generation cephalosporins, the drug Cefditoren should be included in the table.
These errors will be corrected in the September 2012 release of the MY 2012 manual.
There is an error in the manual. In the Table MPM-A: Drugs to Identify Members on ACE Inhibitors or ARBs, in the row Antihypertensive combinations the drugs Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-hydrochlorothiazide-olmesartan and Amlodipine-telmisartan should be included in the table.
This error will be corrected in the September 2012 release of the MY 2012 manual.
There is an error in the manual. In Table CHL-A: Prescriptions to Identify Contraceptives,
in the row Contraceptives, the drugs Estradiol-medroxyprogesterone, Levonorgestrel, Medroxyprogesterone, and Norethindrone should be included in the table,
the drug Levonorgestrel-medroxyprogesterone should not be in the table.
These errors will be corrected in the September 2012 release of the MY 2012 manual.
There is an error in the manual. In the Table AMR-C: Asthma Medications, in the row Inhaled steroid combinations the drug Bluticasone-salmeterol should read Fluticasone-salmeterol.
This error will be corrected in the September 2012 release of the MY 2012 manual.
There is an error in the manual. In Table URI-D: Antibiotic Medications, in the row First generation cephalosporins, the drug Cephradine should not be in the table, in the row Macrolides the drug Erythromycin estolate should not be in the table, in the row Third generation cephalosporins, the drug Cefditoren should be included in the table. These errors will be corrected in the September 2012 release of the MY 2012 manual.
There is an error in the manual. In Table CDC-A: Prescriptions to Identify Members With Diabetes, in the row Miscellaneous antidiabetic agents, the drug Liraglutide should be included in the table.
This error will be corrected in the September 2012 release of the MY 2012 manual.